Clinical Challenge
How Can We Reduce Trial Failures To Accelerate Breakthroughs?
Each year, tens of billions of dollars are lost on clinical trials that fail to deliver new therapies. The vast majority of drug candidates never make it to market, draining resources, time, and hope for biopharma, investors, and patients.
- Global clinical trial spending exceeds $60–80 billion annually, with broader clinical R&D costs reaching $200–250 billion per year.
- Developing a single new drug can cost $1.3–$2.8 billion, with 60–70% of this spent on clinical trials.
- Success rates are low: Only about 10–14% of drugs entering Phase 1 ultimately receive approval.
- Most failures occur in Phase 2 and 3, where the cost and stakes are highest.
- Delays and failures waste years of research, billions in investment, and limit patient access to new treatments.
- If predictive models improved success rates by just 10–15%, the industry could save more than $10–30 billion annually—funds that could be reinvested in more promising therapies and accelerate innovation.